Study Completed

Prevention of venous thromboembolism after MOS

Bayer Identifier:

12361

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

2010-022277-33

EU CT Number:

Not Available

BAY59-7939, Dose proportionality

Trial purpose

Please see attached Study Results Summary below

Key Participants Requirements

Sex

N/A

Age

18 - 45 Years

Trial summary

Enrollment Goal

Trial Dates

November 2010 - February 2011

Phase

Phase 1

Could I Receive a placebo

N/A

Products

Xarelto (Rivaroxaban, BAY59-7939)

Accepts Healthy Volunteer

N/A

Where to participate

Status	Institution	Location
Completed	CRS Clinical-Research-Services Mönchengladbach GmbH	Mönchengladbach, 41061, Germany

Trial design

Randomized, non-blind, non-controlled, 3-way crossover study to assess the pharmacokinetics, safety, and tolerability of different dose strengths of Rivaroxaban (2.5 mg, 5 mg, 10 mg) in healthy male subjects

Trial Type

Interventional

Intervention Type

N/A

Trial Purpose

N/A

Allocation

N/A

Blinding

N/A

Assignment

N/A

Trial Arms

N/A

Additional Information

Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.